Cargando…
Nitroaromatic Hypoxia-Activated Prodrugs for Cancer Therapy
The presence of “hypoxic” tissue (with O(2) levels of <0.1 mmHg) in solid tumours, resulting in quiescent tumour cells distant from blood vessels, but capable of being reactivated by reoxygenation following conventional therapy (radiation or drugs), have long been known as a limitation to success...
Autor principal: | Denny, William A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8878295/ https://www.ncbi.nlm.nih.gov/pubmed/35215299 http://dx.doi.org/10.3390/ph15020187 |
Ejemplares similares
-
Interrogation of the Structure–Activity Relationship of a Lipophilic Nitroaromatic Prodrug Series Designed for Cancer Gene Therapy Applications
por: Ashoorzadeh, Amir, et al.
Publicado: (2022) -
Prodrugs for Gene-Directed Enzyme-Prodrug Therapy (Suicide Gene Therapy)
por: Denny, William A
Publicado: (2003) -
Targeting Hypoxia: Hypoxia-Activated Prodrugs in Cancer Therapy
por: Li, Yue, et al.
Publicado: (2021) -
The Hypoxia-Activated Prodrug TH-302: Exploiting Hypoxia in Cancer Therapy
por: Li, Yue, et al.
Publicado: (2021) -
Hypoxia-activated prodrugs and redox-responsive nanocarriers
por: Zeng, Yun, et al.
Publicado: (2018)